Search NLS News

Hemab Therapeutics has announced the closing of an oversubscribed Series B financing. The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity. All current investors including HealthCap, Novo Holdings, and RA Capital Management also invested. Part of HealthCap’s VIII fund […]

The European Commission has granted conditional marketing authorization (CMA) for CSL’s HEMGENIX, the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B in adults without a history of Factor IX inhibitors. In the ongoing clinical trial, HEMGENIX reduced the rate of annual bleeds with a single infusion by delivering […]

Modus Therapeutics has announced positive top-line data from its lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In this study, healthy volunteers received LPS to induce a transient systemic inflammation reaction together with one of three […]

IRLAB Therapeutics has announced that its CEO Richard Godfrey is leaving his position and that the Board of directors has appointed Gunnar Olsson as Interim CEO. This news follows the disappointing Phase IIb trial results of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs), presented by the company just a few weeks ago. The primary endpoint, […]

The company has announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinibin combination with MSD’s anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC) patients. “We are very encouraged by the topline data,” says Martin Olin, Chief Executive Officer of BerGenBio. “Treatment with bemcentinib in combination with pembrolizumab demonstrated […]

Aqilion has announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with […]

The company has secured funding from the European Innovation Council (EIC) for a project to progress the company’s PeptiCHIP technology. PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalized immunotherapies. Read more: Reinventing immunotherapy – Valo Therapeutics NLS Star 2022 The project, which will be fully funded by the EIC with […]

Biotage has entered into an agreement to acquire Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences. The enterprise value for Astrea is approximately 190 million USD, subject to any closing adjustments and potential milestone-based payments, states the company in a press release. “The acquisition represents an excellent strategic fit for Biotage, and it […]

The Danish Life Science Cluster and the Ministry of Foreign Affairs of Denmark have established a new partnership to create easier access to China for Danish companies within medtech, healthtech and rehabilitation – with a special focus on a designated specialty medical zone. Danish Life Science Cluster, Innovation Center Denmark in Shanghai, The Trade Council […]

Guard Therapeutics have announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has been designed to evaluate the kidney-protective effects of the investigational drug RMC-035 in conjunction with open heart surgery. An interim analysis will be conducted by […]